

Special Issue

Gastric Cancer Research: From Basic Science to the Clinic

Message from the Guest Editor

This Special Issue will focus on understanding the pathophysiology and molecular mechanisms that regulate gastric carcinogenesis and the tools that have been used in the past and are currently available for studying them both in vitro and in vivo. In particular, we will pay attention to the relevance and difference between mouse models and human pathogenesis in the gastric research field. This issue could include reviews, opinions, or short articles from experts in this research field, and cover broad topics such as important histopathological changes and/or key molecular pathways/factors during human and mouse gastric carcinogenesis, the roles of gastric stem cells and their niche during cancer development, the cellular origin of gastric cancers, the tumor microenvironment in gastric cancers, advances in cell lines and primary organoids for gastric research, epidemiological or endoscopic data analysis, and so on. We hope that the works in this issue will be helpful for solving unanswered questions in the clinic, and advancing future basic and clinical studies.

Guest Editor

Dr. Yoku Hayakawa

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Deadline for manuscript submissions

closed (30 September 2019)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/21450

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).